Trial studying safety and effects for Obesity & Overweight
Official title A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers
ClinicalTrials.gov ID: NCT07539415
What this study is testing
What is DWRX5003?
An investigational microneedle patch containing semaglutide being studied as a potential treatment for obesity and overweight. It is designed to deliver semaglutide, a GLP‑1 receptor agonist, which can help regulate appetite and blood sugar.
Also referred to as Semaglutide.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if DWRX5003 is safe and to compare its absorption in the body to two similar compounds.
- Who it's for
- Healthy adult volunteers are needed.
- What's involved
- Participants will receive the study medication and undergo blood draws and other routine checks to monitor safety and drug levels.
- Time commitment
- The trial lasts a few weeks with several clinic visits for dosing and testing.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 to 64. Healthy volunteers may be eligible.
You may be able to join if
- Healthy adult volunteers aged ≥ 19 and ≤ 65 years at screening
- people with a body weight ≥ 50.0 kg to ≤ 100.0 kg and a BMI of ≥ 20.0 kg/m2 to ≤ 29.9 kg/m2 at screening
- people with no congenital disease or chronic disease requiring treatment as well as no pathologic symptoms or findings based on medical examination
- people who are determined to be eligible for this study based on results of laboratory tests, vital signs, physical examination, 12-lead...
- people who voluntarily decided to participate in the study and provided written consent to follow subject compliance requirements during the study...
You likely can't join if
- Females who are pregnant (serum-HCG positive) or breast-feeding
- people with a history of hypersensitivity (e.g., anaphylaxis or angioedema) or clinically significant hypersensitivity to the active ingredient of...
- people with a history of skin disease (e.g., burns, skin cancer, etc.) or skin transplant surgery that could affect the absorption of the...
- people with a history of acute or chronic pancreatitis
- people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2)
- people who are deemed ineligible for participation in the study by the investigator for reasons other than the above inclusion/exclusion criteria etc.
The study team makes the final eligibility decision.
Where it is enrolling
- Seoul, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years to 64 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Seoul, South Korea. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.